163 related articles for article (PubMed ID: 18577244)
1. Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy.
Prete SP; Turriziani M; Massara MC; De Rossi A; Correale P; De Vecchis L; Torino F; Bonmassar L; Aquino A
J Exp Clin Cancer Res; 2008 May; 27(1):5. PubMed ID: 18577244
[TBL] [Abstract][Full Text] [Related]
2. Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells.
Aquino A; Prete SP; Greiner JW; Giuliani A; Graziani G; Turriziani M; De Filippi R; Masci G; Bonmassar E; De Vecchis L
Clin Cancer Res; 1998 Oct; 4(10):2473-81. PubMed ID: 9796980
[TBL] [Abstract][Full Text] [Related]
3. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
Correale P; Cusi MG; Tsang KY; Del Vecchio MT; Marsili S; Placa ML; Intrivici C; Aquino A; Micheli L; Nencini C; Ferrari F; Giorgi G; Bonmassar E; Francini G
J Clin Oncol; 2005 Dec; 23(35):8950-8. PubMed ID: 16061910
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro.
Correale P; Cusi MG; Del Vecchio MT; Aquino A; Prete SP; Tsang KY; Micheli L; Nencini C; La Placa M; Montagnani F; Terrosi C; Caraglia M; Formica V; Giorgi G; Bonmassar E; Francini G
J Immunol; 2005 Jul; 175(2):820-8. PubMed ID: 16002679
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer.
Lee JH; Lee SW
Mol Biol Rep; 2019 Aug; 46(4):3835-3842. PubMed ID: 31028570
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
Kalofonos HP; Aravantinos G; Kosmidis P; Papakostas P; Economopoulos T; Dimopoulos M; Skarlos D; Bamias A; Pectasides D; Chalkidou S; Karina M; Koutras A; Samantas E; Bacoyiannis C; Samelis GF; Basdanis G; Kalfarentzos F; Fountzilas G
Ann Oncol; 2005 Jun; 16(6):869-77. PubMed ID: 15855226
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced changes of carcinoembryonic antigen expression in human cancer cells: effect of 5-fluorouracil.
Prete SP; Aquino A; Masci G; Orlando L; Giuliani A; De Santis S; De Vecchis L; De Filippi R; Greiner JW; Bonmassar E; Graziani G
J Pharmacol Exp Ther; 1996 Dec; 279(3):1574-81. PubMed ID: 8968385
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer.
Gerard B; Bleiberg H; Van Daele D; Gil T; Hendlisz A; Di Leo A; Fernez B; Brienza S
Anticancer Drugs; 1998 Apr; 9(4):301-5. PubMed ID: 9635919
[TBL] [Abstract][Full Text] [Related]
9. Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
Moehler M; Hoffmann T; Hildner K; Siebler J; Galle PR; Heike M
Z Gastroenterol; 2002 Dec; 40(12):957-64. PubMed ID: 12564419
[TBL] [Abstract][Full Text] [Related]
10. Hepatic arterial infusion with oxaliplatin, folinic acid, and 5-fluorouracil in patients with hepatic metastases from colorectal cancer: role of carcino-embryonic antigen in assessment of response.
Kern W; Beckert B; Lang N; Waggershauser T; Braess J; Schalhorn A; Hiddemann W
Anticancer Res; 2000; 20(6D):4973-5. PubMed ID: 11326650
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.
Ohtsukasa S; Okabe S; Yamashita H; Iwai T; Sugihara K
J Cancer Res Clin Oncol; 2003 Dec; 129(12):719-26. PubMed ID: 14564514
[TBL] [Abstract][Full Text] [Related]
12. A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report.
Aquino A; Prete SP; Balduzzi A; Fossile E; Formica V; Torino F; Bonmassar L; Di Giacomo A; Cappelletti D; Cardillo A; Graziani G
J Chemother; 2002 Aug; 14(4):412-6. PubMed ID: 12420861
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
[TBL] [Abstract][Full Text] [Related]
14. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines.
Sørbye H; Dahl O
J Clin Oncol; 2003 Dec; 21(23):4466-7. PubMed ID: 14645446
[No Abstract] [Full Text] [Related]
15. [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Li YH; An X; Xiang XJ; Wang ZQ; Wang FH; Feng F; Jiang WQ; He YJ; Xu RH
Ai Zheng; 2009 Sep; 28(9):939-44. PubMed ID: 19728911
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.
Comella P; Massidda B; Filippelli G; Palmeri S; Natale D; Farris A; De Vita F; Buzzi F; Tafuto S; Maiorino L; Mancarella S; Leo S; Lorusso V; De Lucia L; Roselli M
Ann Oncol; 2005 Jun; 16(6):878-86. PubMed ID: 15837702
[TBL] [Abstract][Full Text] [Related]
17. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
Bécouarn Y; Gamelin E; Coudert B; Négrier S; Pierga JY; Raoul JL; Provençal J; Rixe O; Krisch C; Germa C; Bekradda M; Mignard D; Mousseau M
J Clin Oncol; 2001 Nov; 19(22):4195-201. PubMed ID: 11709562
[TBL] [Abstract][Full Text] [Related]
18. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
20. [A case of local recurrence of colon cancer responding to chemotherapy with low-dose oxaliplatin, 5-FU and l-LV].
Seki H; Kurihara E; Iwata K; Saito J
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1291-3. PubMed ID: 17687216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
